Health Category - Part 3

Case 2 A 43 year old man was evaluated for a two year history of re­current kidney stones with the suspect of pHPT. Measurement of blood and urine calcium in three different days on a diet containing 1 gr/day of calcium and 100 mEq/day of sodium showed circulating total calcium and PTH (1-84) levels at […]

Introduction The diagnosis of primary hyperparathyroidism (pHPT) is based on the finding of normal/high blood calcium levels associated to inadequately high/normal parathyroid hormone (PTH) circulat­ing levels. The majority of cases of pHPT are currently repre­sented by asymptomatic/paucisymptomatic forms of the dis­ease, with little or no progression. Moreover, pHPT is char­acterized by recurrent kidney stones and […]

Sulindac may cause life-threatening adverse reactions involving multiple organ systems. Skin rashes, hepatotox- icity, central nervous system abnormalities, lymphadenopa- thy, pancreatitis, and hypotension have all been associated with sulindac therapy. Two case reports have previously described pulmonary infiltrates and severe adverse reactions to sulindac therapy; however, in these cases the pulmonary findings were associated with […]

Sulindac (Clinoril) is a nonsteroidal anti-inflammatory agent commonly used in the treatment of arthritis. Serious life-threatening adverse reactions can occur with sulindac therapy, but isolated pulmonary infiltrates are extremely rare. This report describes a patient with fever, dyspnea, cough, and diffuse, bilateral pulmonary infiltrates which were temporally related to sulindac therapy. Case Report A 62-year-old […]

Limitations This study had several limitations. The short time frame (6 months) did not allow analysis of temporal trends in milrinone use. The use of logistic regression, which focuses on the presence or absence of an event, prevented us from capturing the time course (i.e., onset, frequency, duration) of outcomes. The time course of independent […]

Association of Milrinone Dosing with Efficacy Despite the fact that for most admissions (80.3%) the patient started milrinone before admission to the CCU, low cardiac output syndrome during the CCU stay was common (76.1%). This frequency was nearly twice the 45% reported in the Prophylactic Intravenous Use of Milrinone after Cardiac Operation in Pediatrics (PRIMACORP) […]

This retrospective study involved a cohort of 197 patients representing 213 admissions to the CCU over a 6-month peri­od. The median initial loading dose was 99.2 Hg/kg, and the median infusion rate was 0.64 Hg/kg per minute for a median duration of 43.1 hours. Milrinone duration was significantly associated with low cardiac output syndrome, but […]